Ignite Creation Date:
2024-05-05 @ 7:35 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00697632
Status:
COMPLETED
Last Update Posted:
2019-02-12
First Post:
2008-05-14
Brief Title:
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Study Overview
Official Title:
Open-Label Dose-Escalation Trial to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study MGCD265 a new anticancer drug under investigation is given daily to patients with advanced malignancies to study its safety profile
Detailed Description:
MGCD265 belongs to a new class of drugs with anticancer potential known as tyrosine kinase inhibitors MGCD265 was shown to slow down the growth of human cancer cells in mice Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients
In this study MGCD265 is orally administered on a daily basis to patients with advanced malignancies
In this study MGCD265 is orally administered on a daily basis to patients with advanced malignancies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None